- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02904759
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
September 9, 2019 updated by: Ferring Pharmaceuticals
A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
The purpose of this trial is to demonstrate efficacy of desmopressin ODT against placebo for the treatment of male subjects with nocturia due to nocturnal polyuria, during 12 weeks of treatment.
Study Overview
Study Type
Interventional
Enrollment (Actual)
342
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Investigational site (there may be other sites in this country)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Written informed consent prior to performance of any trial-related activity
- Man ≥20 years of age
- Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1
- ≥2 nocturnal voids at the end of screening period prior to Visit 2
- Nocturnal polyuria at the end of screening period prior to Visit 2
- Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1 and Visit 2
- Has given agreement about contraception during the trial
Exclusion Criteria:
- Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 2
- History or evidence of significant obstructive sleep apnoea
History or diagnosis of any of the following urological diseases at Visit 1:
- Interstitial cystitis or bladder pain disorder
Suspicion of moderate or severe benign prostate hyperplasia (BPH), defined as international prostate symptom score (IPSS) ≥8 points and:
- Urinary flow <5 mL/s or
- Post-void residual volume >150 mL
- Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history
- Chronic pelvic pain syndrome
- Surgical treatment, including transurethral resection, for bladder outlet obstruction (BOO) or BPH within the past 6 months prior to Visit 1
Symptoms of severe over-active bladder (OAB):
- Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1
- Defined as a mean of >8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 2
- Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1
- Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1
- Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1
- History of any neurological disease affecting bladder function or muscle strength at Visit 1
- Habitual or psychogenic polydipsia based on medical history at Visit 1 or 24 hour urine output of >2.8 L based on the voiding diary at Visit 2
- Central or nephrogenic diabetes insipidus at Visit 1
- Syndrome of inappropriate antidiuretic hormone secretion at Visit 1
- Suspicion or evidence of cardiac failure at Visit 1
- Uncontrolled hypertension at Visit 1
- Uncontrolled diabetes mellitus at Visit 1
- Hyponatraemia (serum sodium level <135 mmol/L) at Visit 1
- Renal insufficiency at Visit 1
- Hepatic and/or biliary diseases at Visit 1
- Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1
- Known alcohol or substance abuse at Visit 1
- Work or lifestyle that may interfere with regular night-time sleep at Visit 1, e.g., shift workers
- Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1
- Use of any prohibited therapy during the trial period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo ODT
|
|
Experimental: Desmopressin 25 µg
Desmopressin ODT
|
Other Names:
|
Experimental: Desmopressin 50 µg
Desmopressin ODT
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean number of nocturnal voids during 12 weeks of treatment
Time Frame: Week 1, 4, 8 and 12
|
Assessed by the 3-day voiding diary
|
Week 1, 4, 8 and 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean time to first awakening to void
Time Frame: Week 1, 4, 8 and 12
|
Assessed by the 3-day voiding diary
|
Week 1, 4, 8 and 12
|
Change from baseline in mean nocturnal urine volume
Time Frame: Week 1, 4, 8 and 12
|
Assessed by the 3-day voiding diary
|
Week 1, 4, 8 and 12
|
Change from baseline in mean Nocturnal Polyuria Index (NPI)
Time Frame: Week 1, 4, 8 and 12
|
Assessed by the 3-day voiding diary
|
Week 1, 4, 8 and 12
|
Change from baseline in Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)
Time Frame: Week 8 and 12
|
Week 8 and 12
|
|
Change from baseline in Insomnia Severity Index (ISI)
Time Frame: Week 8 and 12
|
Week 8 and 12
|
|
Change from baseline in bother score
Time Frame: Week 8 and 12
|
Assessed by the Hsu 5-point Likert bother scale
|
Week 8 and 12
|
Frequency and severity of adverse events
Time Frame: From screening to week 12
|
From screening to week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2016
Primary Completion (Actual)
September 29, 2017
Study Completion (Actual)
September 29, 2017
Study Registration Dates
First Submitted
September 14, 2016
First Submitted That Met QC Criteria
September 16, 2016
First Posted (Estimate)
September 19, 2016
Study Record Updates
Last Update Posted (Actual)
September 11, 2019
Last Update Submitted That Met QC Criteria
September 9, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 000130
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nocturia
-
Winthrop University HospitalCompleted
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
Ferring PharmaceuticalsCompletedNocturia Associated With Nocturnal PolyuriaGermany
-
Wellesley Pharmaceuticals, LLCCompleted
-
Ferring PharmaceuticalsCompletedNocturiaUnited States
-
Corporacion Parc TauliCompleted
-
Ferring PharmaceuticalsCompleted
-
Cognitive Research CorporationNovartis PharmaceuticalsWithdrawn
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States